Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Hut 8 Corp (HUT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Hut 8 Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Hut 8 Corp trades at $100.72 (market cap $11.50B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.5× Hut 8 Corp's market cap, and Hut 8 Corp is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | HUT | |
|---|---|---|
Market Cap | $39.89B | $11.50B |
Sector | Health | Technology |
52-Week High | $491.22 | $133.02 |
52-Week Low | $278.09 | $19.45 |
Enterprise Value | $38.15B | $11.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
HUT trades at $102.22, down 3.77% over 24 hours, with a bearish technical signal and key support at $98. The company reported a net loss of $226.15 million in 2025 despite revenue growth, but recent earnings beats and a strategic pivot to AI infrastructure have driven positive analyst sentiment. Strong institutional backing is evident with $4.25 billion in project financing secured in June 2026.
Outlook remains speculative with high execution risk amid the business transition, though Wall Street consensus is bullish with a $135.63 price target. Key risks include sustained negative cash flow, competitive pressures in data centers, and reliance on successful AI project deployment to achieve profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Hut 8 Corp
Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →
